Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Bevacizumab Biosimilar With or Without HAIC for Advanced Hepatocellular Carcinoma
NCT06860490Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, folinic acid, fluorouracil in hepatocellular carcinoma (HCC), sponsored by Fudan University. Started Mar 2025; status: recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06860490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860490.